Notable Publications
T. Ewen, et al. authors
Validation of Epidermal AMBRA1 and Loricrin (AMBLor) as a prognostic biomarker for non-ulcerated AJCC stage I/II cutaneous melanoma
Br J Dermatol, ljad459, https://doi.org/10.1093/bjd/ljad459, 25 November 2023
P. Lovat, et al. authors
Discovery and validation of AMBLor as a prognostic biomarker for non-ulcerated cutaneous AJCC stage I/II melanoma
J Clin Onc, ASCO Abstract (Poster), 2023 Jun; 9573
T.W. Andrew, et al. authors
Performance analysis of four machine learning algorithms for the accurate prediction of metastatic disease in cutaneous squamous cell carcinoma
J Clin Onc, ASCO Abstract, 2023 Jun; e1357
I. Cosgarea, A. McConnell, T. Ewen, et al. authors
Melanoma secretion of transforming growth factor-β2 leads to loss of epidermal AMBRA1 threatening epidermal integrity and facilitating tumour ulceration
Br J Dermatol, Volume 186, Issue 4, 1 April 2022, 694–704. https://doi.org/10.1111/bjd.20889
T.W. Andrew, P. Lovat, N. Alham, C. Verrill, N. Stefanos, et al. authors
Artificial Intelligence for Risk Classification of AMBLor in the melanoma microenvironment
Pigment Cell and Melanoma Research 2021; 35(1), 98.
T. Ewen, G. Paragh, P. Bogner, et al. authors
Validation of AMBLor as a prognostic biomarker for non-ulcerated cutaneous AJCC stage I/II Melanoma
Pigment Cell and Melanoma Research 2021; 35(1), 117—118.
L. Vale, K. Kunonga, D. Coughlan, et al. authors
Optimal surveillance strategies for Patients with stage 1 cutaneous melanoma post primary tumour excision: three systematic reviews and an economic model
NIHR Journals 2021.
M. Labus, R. Ellis, T. Ewen, et al. authors
AMBLor: A prognostic and stratifying biomarker for adjuvant immunotherapy of AJCC stage II melanomas
Journal of Clinical Oncology 2020; 38(15).
R. Ellis, A. McConnell, M. Labus, P.E. Lovat, et al. authors
Epidermal autophagy and beclin 1 regulator 1 and loricrin: a paradigm shift in the prognostication and stratification of the American Joint Committee on Cancer stage I melanomas
Br J Dermatol. 2020 Jan; 182(1):156—165.
D. Coughlan, V. Kontogiannis, L. Vale, et al. authors
Prognostic biomarker AMBLor in surveillance strategies for AJCC Stage 1 Melanoma: A cost-effectiveness analysis
Pigment Cell and Melanoma Research 2019; 33(1), 163—164.
R. Ellis, T. Ewen, D. Bajwa, A. Greenwood, et al. authors
AMBLor: A stratifying biomarker for adjuvant immunotherapy of AJCC stage II melanoma
Pigment Cell and Melanoma Research 2019; 33(1), 204.
A. McConnell, D. Bajwa, J. Allen, et al. authors
AMBRA1 and loricrin: A paradigm shift in early melanoma prognostication
Br J Dermatol. 2019; 180(6), e196—e197.
Job code: 2022/AMBLor/UK/0015(2)a
Date of preparation: January 2022
AMLo Biosciences Limited is a company registered in England and Wales. Company # 11004534
Trading address (Visitors and Deliveries): Office 9, The Biosphere, Drayman's Way, Newcastle Helix, Newcastle upon Tyne, NE4 5BX ///wider.admire.guard
Registered address: c/o RMT Accountants & Business Advisors Ltd, Gosforth Park Avenue, Newcastle upon Tyne, NE12 8EG, United Kingdom
VAT # 285288950
Sign up for our newsletter